Trial Profile
A Randomized Discontinuation Phase II Trial of Deforolimus (Ridaforolimus) in Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS Mutations.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors ARIAD Pharmaceuticals; Merck Sharp & Dohme
- 18 May 2012 Planned end date changed from 1 Apr 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 03 Aug 2011 Status changed from active, no longer recruiting to discontinued.
- 07 Jul 2011 Primary endpoint 'Progression-free-survival-duration' has not been met.